2025/26 publications

Between 1 April 2025 and 31 March 2026, the following articles were published which relate to studies that have been supported by the NIHR Sheffield Clinical Research Facility (CRF).

Interleukin-1 receptor antagonist polymorphisms in women receiving epidural analgesia who develop maternal intrapartum fever: a prospective, multicentre Mendelian randomised study (STH21650: EPIFEVER-2)

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (STH21355: RECOVERY)

Clinical and cost-effectiveness of diverse posthospitalisation pathways for COVID-19: a UK evaluation using the PHOSP-COVID cohort (STH21439: PHOSP-COVID)

Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity (STH21439: PHOSP-COVID)

Post-Hospitalisation COVID-19 Rehabilitation (PHOSP-R): a randomised controlled trial of exercise-based rehabilitation (STH21439: PHOSP-COVID)

Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury (STH21439: PHOSP-COVID)

The safety, physiological response and repeatability of the incremental shuttle walk test in survivors of COVID-19 (STH21439: PHOSP-COVID)

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial (STH18069: MIROCALS-IL2)

Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity (STH21428: PAN-NPC (COVID-CNS))

Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity (STH16436: PAH BioBank)

Serum mesothelin as a response biomarker in pleural mesothelioma (STH20915: ASSESS-meso)

Investigating the impact of dipeptidyl peptidase-1 inhibition in humans using multi-omics (STH21421: STOP-COVID19)

The effectiveness of Rituximab in the real-world treatment of lupus nephritis: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) (STH15729: BILAG)